Melanoma Research Reagents: BRAF, Immune Checkpoint & Melanocyte Markers

Melanoma has been at the forefront of immuno-oncology, serving as the proving ground for both CTLA-4 (ipilimumab, 2011) and PD-1 (pembrolizumab/nivolumab, 2014) checkpoint blockade, as well as the first LAG-3 combination (relatlimab + nivolumab, 2022). For a broader view of all oncology reagent categories, see our Cancer Research Reagents hub.

Key Targets and Biomarkers

BRAF V600E/K mutations occur in ~50% of cutaneous melanomas. Anti-BRAF V600E antibody (clone VE1) enables rapid IHC-based mutation screening on FFPE tissue. Wild-type BRAF melanomas are typically NRAS-mutant (~20%) or NF1-mutant (~15%).

Melanocyte lineage markers for IHC diagnosis: SOX10 (nuclear; most sensitive), S100 (nuclear + cytoplasmic; most commonly used), MITF (nuclear), Melan-A/MART-1 (cytoplasmic), HMB-45/gp100 (cytoplasmic). A panel approach (SOX10 + S100 + Melan-A) provides the highest diagnostic sensitivity. For guidance on building diagnostic IHC panels, see our IHC Panel Design guide.

Melanoma is highly immunogenic, with high tumor mutational burden (TMB) generating neoantigens that drive T cell responses. The tumor microenvironment in melanoma is a major focus of research, with TIL density and PD-L1 expression serving as predictive biomarkers for checkpoint immunotherapy response. For TIL phenotyping by flow cytometry, see our Flow Cytometry for TIL Analysis guide.

Research biosimilar versions of ipilimumab (anti-CTLA-4), pembrolizumab (anti-PD-1), nivolumab (anti-PD-1), and relatlimab (anti-LAG-3) are all available for melanoma preclinical research and bioanalytical assay development.

References

1. Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019;20(11):1366-1379. doi: 10.1080/15384047.2019.1640032

2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264. doi: 10.1038/nrc3239

3. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069-1086. doi: 10.1158/2159-8290.CD-18-0367

All products are for research use only. For technical support, contact order@abinscience.com.